Jacobio Pharmaceuticals Group Co., Ltd. 1167
HKEX · Hong Kong SAR China · Health Technology
HKD 5.76-0.30 (-4.95%)
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As of June 2026, Asian markets are navigating a complex landscape marked by mixed economic signals and geopolitical tensions. Despite these challenges, opportunities remain for investors willing to explore beyond the established giants. Penny stocks, often representing smaller or newer companies, continue to capture attention due to their potential for significant returns when backed by strong financials. In this article, we explore three such stocks that stand out for their balance sheet...
Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.